WO2005048940A2 - Nutraceutical mangosteen tea - Google Patents

Nutraceutical mangosteen tea Download PDF

Info

Publication number
WO2005048940A2
WO2005048940A2 PCT/US2004/038003 US2004038003W WO2005048940A2 WO 2005048940 A2 WO2005048940 A2 WO 2005048940A2 US 2004038003 W US2004038003 W US 2004038003W WO 2005048940 A2 WO2005048940 A2 WO 2005048940A2
Authority
WO
WIPO (PCT)
Prior art keywords
nutraceutical
tea composition
plant
vitamin
fruit
Prior art date
Application number
PCT/US2004/038003
Other languages
French (fr)
Other versions
WO2005048940A3 (en
Inventor
Aaron R. Garrity
Joseph C. Morton
Paula Morrison
Victoria De La Huerga
Original Assignee
Dbc, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dbc, Llc filed Critical Dbc, Llc
Priority to BRPI0416594-2A priority Critical patent/BRPI0416594A/en
Priority to EP04810952A priority patent/EP1691758A4/en
Priority to AU2004291117A priority patent/AU2004291117A1/en
Priority to CA002545819A priority patent/CA2545819A1/en
Priority to JP2006539951A priority patent/JP2007511224A/en
Publication of WO2005048940A2 publication Critical patent/WO2005048940A2/en
Publication of WO2005048940A3 publication Critical patent/WO2005048940A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae

Definitions

  • the presently described technology relates to a nutraceutical tea composition comprising xanthone compounds. More particularly, the presently described technology relates to a nutraceutical tea composition comprising xanthones derived from, for example, fruit of the Garcinia mangostana L. plant, otherwise known as the mangosteen plant.
  • Tea beverages have a long and storied history. It is said that around 2500 BC, the Chinese Emperor Shen-Nung was one day boiling his drinldng water when a few leaves from a branch over the pot fell into the water. The resulting aroma was delicious, and a new beverage was born from the leaves of the wild tea plant. Cultivation of tea spread from China to Japan and eventually the drink was introduced to Europe. The Boston Tea Party was a famous event in early American history that demonstrates the widespread popularity of tea beverages at that time. Today, tea is a staple beverage around the world.
  • teas are known for their health benefits. Indeed, tea is extremely rich in chemicals called alkylamines, which have been shown to boost immune cells in the human body. Recent medical studies have indicated that teas may be positively associated with a number of health benefits, including reduced risk of cardiovascular disease and a lower incidence of some forms of cancer, hi addition, many teas are known to have high levels of antioxidants.
  • a tea beverage comprising natural xanthones.
  • a mangosteen tea beverage combining the benefits of xanthone compounds with the medicinal qualities tea.
  • a mangosteen tea beverage comprising xanthones from the pericarp and fruit pulp of the mangosteen plant.
  • nutraceutical tea compositions comprising xanthone compounds.
  • the presently described technology provides a nutraceutical tea composition containing one or more ingredients selected from the group consisting of leave teas, herbal teas, tea extracts, and combinations thereof; and at least one xanthone.
  • the nutraceutical tea composition can further contain vitamins, minerals, food-grade sweeteners, or a combination thereof.
  • xanthones to be used in the presently described technology are derived from natural plant sources, especially from fruit of Garcinia mangostana L. plant.
  • the pericarp of the fruit of Garcinia mangostana L. plant can be used alone or in combination with the pulp of the fruit to provide an excellent source of xanthones.
  • Teas are derived from a variety of different plant sources. In general, for example, there are three types of leaf teas: green tea, which is non-fermented, oolong tea, which is slightly fermented, and black or red tea, which are fully fermented.
  • green tea which is non-fermented
  • oolong tea which is slightly fermented
  • red tea which are fully fermented.
  • One of the main steps in manufacturing leaf tea is the degree of fermentation the tea leaves are allowed to undergo. The amount of fermentation determines the type of tea that is produced. Tea fermentation usually refers to the level of enzymatic oxidation that naturally occurs when fresh tea leaves begin to dry. This natural oxidation process can be stopped by pan frying or steaming the tea leaves before they are completely dried.
  • the natural xanthones from the mangosteen plant can be combined with one or more leave teas, herbal teas, tea extracts, or a combination thereof to form a nutraceutical mangosteen tea beverage.
  • the xanthones used in the presently described technology may be derived from a number of different sources.
  • the xanthones are natural xanthones derived from the pericarp or fruit pulp or the whole fruit of the fruit of the Garcinia mangostana L. plant, although other sources would also be efficacious.
  • whole mangosteen fruit is ground into a pericarp-fruit pulp mixture. Water is then removed from the mixture through standard techniques of dehydration well know in the industry, including vacuum dehydration. The resulting dehydrated mixture of natural xanthones derived from the pericarp and fruit pulp of the mangosteen fruit is an excellent source of natural, holistic xanthone compounds.
  • the xanthones are extracted from a mangosteen whole fruit mixture or from the pericarp of the mangosteen fruit.
  • Rooibos tea comes from the Aspalathus linearis L. plant, otherwise known as the Rooibos plant. This plant is part of the Aspalathus plant group, which consists of more than 200 species that occur only in South Africa.
  • the Aspalathus linearis L. plant is known to reduce the symptoms of insomnia, irritability, headaches, nervous tension, and hypertension.
  • xanthones from the Garcinia mangostana L. plant and the Aspalathus linearis L. plant yields a beneficial nutraceutical composition having surprising health properties.
  • xanthones from the mangosteen plant are combined with one or more herbal teas selected from the group consisting of burdock, cardamom, chamomile, cinnamon, damiana, dandelion, fennel, ginger, hawthorn, kava kava, lemon balm, licorice, mint, motherwort, nettle, raspberry, rosehip, rosemary, sage, skullcap, st.
  • a mixture of pericarp and fruit pulp from the mangosteen fruit, in either a wet or dehydrated form, is mixed with teas selected from the group consisting of burdock, cardamom, chamomile, cinnamon, damiana, dandelion, fennel, ginger, hawthorn, kava kava, lemon balm, licorice, mint, motherwort, nettle, raspberry, rosehip, rosemary, sage, skullcap, st.
  • teas selected from the group consisting of burdock, cardamom, chamomile, cinnamon, damiana, dandelion, fennel, ginger, hawthorn, kava kava, lemon balm, licorice, mint, motherwort, nettle, raspberry, rosehip, rosemary, sage, skullcap, st.
  • teas selected from the group consisting of burdock, cardamom, chamomile, cinnamon, damiana, dandelion, fennel, ginger
  • the presently described technology may also be fortified with vitamins and minerals, to provide additional health and energy benefits.
  • vitamins and minerals suitable for incorporation in the compositions of the presently described technology include vitamin A, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, thiamin, riboflavin, niacin, biotin acceptable forms of panthotenic acid,' calcium, sodium, potassium, phosphorous, magnesium, manganese, copper, zinc, iron, selenium, chromium and molybdenum.
  • the presently described technology may also include common food-grade sweeteners such as glucose, dextrose, fructose, lactose, maltose, xylose, sucrose, corn sugar syrup, and high fructose com syrup.
  • common food-grade sweeteners such as glucose, dextrose, fructose, lactose, maltose, xylose, sucrose, corn sugar syrup, and high fructose com syrup.
  • a nutraceutical mangosteen tea was made by diluting high fructose corn syrup to a Brix value of 10.38, adding vitamin C at 100% RDI per 8 oz., adding a mixture of mangosteen pericarp and fruit pulp and adding natural rooibos tea extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Tea And Coffee (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A nutraceutical tea composition containing xanthone compounds is disclosed. The xanthones contained in the tea composition are, preferably, derived from fruit of the Garcinia mangostana L. plant, otherwise known as the mangosteen plant.

Description

NUTRACEUTICALMANGOSTEENTEA FIELD OF THE INVENTION [0001] The presently described technology relates to a nutraceutical tea composition comprising xanthone compounds. More particularly, the presently described technology relates to a nutraceutical tea composition comprising xanthones derived from, for example, fruit of the Garcinia mangostana L. plant, otherwise known as the mangosteen plant.
BACKGROUND OF THE INVENTION [0002] Tea beverages have a long and storied history. It is said that around 2500 BC, the Chinese Emperor Shen-Nung was one day boiling his drinldng water when a few leaves from a branch over the pot fell into the water. The resulting aroma was delicious, and a new beverage was born from the leaves of the wild tea plant. Cultivation of tea spread from China to Japan and eventually the drink was introduced to Europe. The Boston Tea Party was a famous event in early American history that demonstrates the widespread popularity of tea beverages at that time. Today, tea is a staple beverage around the world.
[0003] Many teas are known for their health benefits. Indeed, tea is extremely rich in chemicals called alkylamines, which have been shown to boost immune cells in the human body. Recent medical studies have indicated that teas may be positively associated with a number of health benefits, including reduced risk of cardiovascular disease and a lower incidence of some forms of cancer, hi addition, many teas are known to have high levels of antioxidants.
[0004] The medicinal properties of the Garcinia mangostana L. plant have increasingly been the subject of recent pharmacological and clinical studies. These studies have shown that some of the natural compounds derived from the plant yield surprising medicinal benefits, especially the xanthone compounds. The history of the Garcinia mangostana L. plant and the pharmacological benefits of individual xanthone compounds are described in more particular detail in U.S. Patent No. 6,730,333 (Garrity et al.), which is incorporated herein by reference. [0005] Despite the known use of teas and the documented medicinal benefits of xanthones, there exists a need in the art for a nutraceutical composition offering the advantages of xanthone compounds in a tea beverage. Moreover, there is a need in the art for a tea beverage comprising natural xanthones. There is a further need in the art for a mangosteen tea beverage combining the benefits of xanthone compounds with the medicinal qualities tea. There is an additional need in the art for a mangosteen tea beverage comprising xanthones from the pericarp and fruit pulp of the mangosteen plant.
BRIEF SUMMARY OF THE INVENTION [0006] The presently described technology relates to nutraceutical tea compositions comprising xanthone compounds.
[0007] In one aspect, the presently described technology provides a nutraceutical tea composition containing one or more ingredients selected from the group consisting of leave teas, herbal teas, tea extracts, and combinations thereof; and at least one xanthone. The nutraceutical tea composition can further contain vitamins, minerals, food-grade sweeteners, or a combination thereof.
[0008] Preferably, xanthones to be used in the presently described technology are derived from natural plant sources, especially from fruit of Garcinia mangostana L. plant. For example, the pericarp of the fruit of Garcinia mangostana L. plant can be used alone or in combination with the pulp of the fruit to provide an excellent source of xanthones.
BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS [0009] [Not Applicable]
DETAILED DESCRIPTION OF THE INVENTION [0010] It is understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to limit the scope of the presently described technology. It is also understood that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference, unless the context clearly dictates otherwise. [0011] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. While various methods, compositions, and materials of the presently described technology are described herein, any methods and materials similar or equivalent to those described herein can by used in the practice or testing of the presently described technology. All references cited herein are incorporated by reference in their entirety.
[0012] Teas are derived from a variety of different plant sources. In general, for example, there are three types of leaf teas: green tea, which is non-fermented, oolong tea, which is slightly fermented, and black or red tea, which are fully fermented. One of the main steps in manufacturing leaf tea is the degree of fermentation the tea leaves are allowed to undergo. The amount of fermentation determines the type of tea that is produced. Tea fermentation usually refers to the level of enzymatic oxidation that naturally occurs when fresh tea leaves begin to dry. This natural oxidation process can be stopped by pan frying or steaming the tea leaves before they are completely dried.
[0013] In accordance with one embodiment of the presently described technology, the natural xanthones from the mangosteen plant can be combined with one or more leave teas, herbal teas, tea extracts, or a combination thereof to form a nutraceutical mangosteen tea beverage.
[0014] The xanthones used in the presently described technology may be derived from a number of different sources. Preferably, the xanthones are natural xanthones derived from the pericarp or fruit pulp or the whole fruit of the fruit of the Garcinia mangostana L. plant, although other sources would also be efficacious. In one embodiment of the presently described technology, whole mangosteen fruit is ground into a pericarp-fruit pulp mixture. Water is then removed from the mixture through standard techniques of dehydration well know in the industry, including vacuum dehydration. The resulting dehydrated mixture of natural xanthones derived from the pericarp and fruit pulp of the mangosteen fruit is an excellent source of natural, holistic xanthone compounds. In another embodiment of the presently described technology, the xanthones are extracted from a mangosteen whole fruit mixture or from the pericarp of the mangosteen fruit.
[0015] The synergistic effect of the mangosteen xanthones with selected teas yields a nutraceutical tea beverage that offers surprising health benefits. [0016] In a further embodiment of the presently described technology, the mangosteen xanthones are combined with rooibos tea extract. Rooibos tea comes from the Aspalathus linearis L. plant, otherwise known as the Rooibos plant. This plant is part of the Aspalathus plant group, which consists of more than 200 species that occur only in South Africa. The Aspalathus linearis L. plant is known to reduce the symptoms of insomnia, irritability, headaches, nervous tension, and hypertension. It is also known to have a beneficial effect on hay fever, asthma and eczema. The combination of xanthones from the Garcinia mangostana L. plant and the Aspalathus linearis L. plant yields a beneficial nutraceutical composition having surprising health properties. [0017] In other embodiments of the presently described technology, xanthones from the mangosteen plant are combined with one or more herbal teas selected from the group consisting of burdock, cardamom, chamomile, cinnamon, damiana, dandelion, fennel, ginger, hawthorn, kava kava, lemon balm, licorice, mint, motherwort, nettle, raspberry, rosehip, rosemary, sage, skullcap, st. John's wort, strawbeπ-y, thyme, valerian and yarrow. In a preferred embodiment of the presently described technology, a mixture of pericarp and fruit pulp from the mangosteen fruit, in either a wet or dehydrated form, is mixed with teas selected from the group consisting of burdock, cardamom, chamomile, cinnamon, damiana, dandelion, fennel, ginger, hawthorn, kava kava, lemon balm, licorice, mint, motherwort, nettle, raspberry, rosehip, rosemary, sage, skullcap, st. John's wort, strawberry, thyme, valerian, yarrow rooibos, and combinations thereof.
[0018] The presently described technology may also be fortified with vitamins and minerals, to provide additional health and energy benefits. Although there is no limit as to the type and variety of vitamins and minerals that can be employed with the presently described technology, and such lαiowledge is well within the realm of one of ordinary skill in the art, examples of vitamins and minerals suitable for incorporation in the compositions of the presently described technology include vitamin A, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, thiamin, riboflavin, niacin, biotin acceptable forms of panthotenic acid,' calcium, sodium, potassium, phosphorous, magnesium, manganese, copper, zinc, iron, selenium, chromium and molybdenum.
[0019] The presently described technology may also include common food-grade sweeteners such as glucose, dextrose, fructose, lactose, maltose, xylose, sucrose, corn sugar syrup, and high fructose com syrup. [0020] The invention will now be explained with reference to the following examples, which are given for illustration only and are not intended to be limiting thereof.
Example 1
[0021] A nutraceutical mangosteen tea was made by diluting high fructose corn syrup to a Brix value of 10.38, adding vitamin C at 100% RDI per 8 oz., adding a mixture of mangosteen pericarp and fruit pulp and adding natural rooibos tea extract.
[0022] The presently described technology may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the presently described technology is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims

CLAIMS What is claimed is:
1. A nutraceutical tea composition comprising: one or more ingredients selected from the group consisting of leave teas, herbal teas, tea extracts, and combinations thereof; and at least one xanthone.
2. The nutraceutical tea composition of claim 1 and further comprising at least one ingredient selected from the group consisting of vitamins, minerals, food- grade sweeteners, and combinations thereof.
3. The nutraceutical tea composition of claim 1, wherein the at least one xanthone is derived from natural plant sources.
4. The nutraceutical tea composition of claim 1, wherein the at least one xanthone is derived from fruit of Garcinia mangostana L. plant.
5. The nutraceutical tea composition of claim 1, wherein the at least one xanthone is derived from pericarp of fruit of Garcinia mangostana L. plant.
6. The nutraceutical tea composition of claim 1, wherein the at least one xanthone is derived from a mixture of pulp and pericarp of fruit of Garcinia mangostana L. plant.
7. The nutraceutical tea composition of claim 1, wherein the at least one xanthone is derived from fruit of Garcinia mangostana L. plant by a process comprising grinding whole fruit of Garcinia mangostana L. plant into a mixture of pericarp and fruit pulp, wherein the mixture is used to make the nutraceutical mangosteen tea composition.
8. The nutraceutical tea composition of claim 7, wherein the mixture of pericarp and fruit pulp is dehydrated.
9. The nutraceutical tea composition of claim 1, wherein the at least one xanthone is derived from fruit of Garcinia mangostana L. plant by a process comprising: grinding whole fruit of Garcinia mangostana L. plant into a mixture of pericarp and fruit pulp; and extracting xanthones from the mixture.
10. The nutraceutical tea composition of claim 1, wherein the leave teas are selected from the group consisting of green teas, oolong teas, fully fermented teas, and combinations thereof.
11. The nutraceutical tea composition of claim 1, wherein the tea extracts are rooibos tea extracts.
12. The nutraceutical tea composition of claim 11, wherein the rooibos tea extracts are from Aspalathus linearis L. plant.
13. The nutraceutical tea composition of claim 1, wherein the herbal teas are selected from the group consisting of burdock, cardamom, chamomile, cinnamon, damiana, dandelion, fennel, ginger, hawthorn, kava kava, lemon balm, licorice, mint, motherwort, nettle, raspberry, rosehip, rosemary, sage, skullcap, st. John's wort, strawberry, thyme, valerian, yarrow, and combinations thereof.
14. The nutraceutical tea composition of claim 2, wherein the vitamins and minerals are selected from the group consisting of vitamin A, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, thiamin, riboflavin, niacin, biotin acceptable forms of panthotenic acid, calcium, sodium, potassium, phosphorous, magnesium, manganese, copper, zinc, iron, selenium, chromium, molybdenum, and combinations thereof.
5. The nutraceutical tea composition of claim 2, wherein the food-grade sweeteners are selected from the group consisting of glucose, dextrose, fructose, lactose, maltose, xylose, sucrose, com sugar syrup, high fructose com syrup, and combinations thereof.
PCT/US2004/038003 2003-11-13 2004-11-12 Nutraceutical mangosteen tea WO2005048940A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0416594-2A BRPI0416594A (en) 2003-11-13 2004-11-12 nutritious mangosteen tea composition
EP04810952A EP1691758A4 (en) 2003-11-13 2004-11-12 Nutraceutical mangosteen tea
AU2004291117A AU2004291117A1 (en) 2003-11-13 2004-11-12 Nutraceutical mangosteen tea
CA002545819A CA2545819A1 (en) 2003-11-13 2004-11-12 Nutraceutical mangosteen tea
JP2006539951A JP2007511224A (en) 2003-11-13 2004-11-12 Mangosteen tea for nutrition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51985403P 2003-11-13 2003-11-13
US60/519,854 2003-11-13

Publications (2)

Publication Number Publication Date
WO2005048940A2 true WO2005048940A2 (en) 2005-06-02
WO2005048940A3 WO2005048940A3 (en) 2005-07-28

Family

ID=34619385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/038003 WO2005048940A2 (en) 2003-11-13 2004-11-12 Nutraceutical mangosteen tea

Country Status (9)

Country Link
US (1) US20050196511A1 (en)
EP (1) EP1691758A4 (en)
JP (1) JP2007511224A (en)
KR (1) KR20060128887A (en)
CN (1) CN1889967A (en)
AU (1) AU2004291117A1 (en)
BR (1) BRPI0416594A (en)
CA (1) CA2545819A1 (en)
WO (1) WO2005048940A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235533B1 (en) 1998-03-18 2001-05-22 Amcol International Corporation Method of determining the composition of clay deposit
WO2011106417A2 (en) * 2010-02-23 2011-09-01 Tahitian Noni International, Inc. Garcinia mangostana l. and iridoid based formulations
EP3354254A4 (en) * 2015-09-21 2019-03-27 Industry-Academic Cooperation Foundation Gyeongsang National University Skin whitening composition containing beta-mangostin as active ingredient
RU2737701C1 (en) * 2020-06-17 2020-12-02 Андрей Михайлович Гомжин Pharmaceutical composition of sedative and anxiolytic action

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1824442A4 (en) * 2004-11-16 2009-11-11 Renaissance Herbs Inc Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
KR101337895B1 (en) * 2007-10-18 2013-12-09 (주)아모레퍼시픽 Mixed cherry-flavored green tea with excellent preference and the method for manufacturing thereof
KR101359948B1 (en) * 2007-10-31 2014-02-11 (주)아모레퍼시픽 Goldmedalist-flavored mixed tea with excellent preference and the method for preparing thereof
KR101493316B1 (en) * 2008-07-22 2015-02-16 (주)아모레퍼시픽 Tea for improving leg edema having good taste
US20110151031A1 (en) * 2008-08-19 2011-06-23 Dbc, Llc Compositions and methods for utilizing the same
WO2011153298A1 (en) 2010-06-03 2011-12-08 Hsio Technologies, Llc Electrical connector insulator housing
US8955215B2 (en) 2009-05-28 2015-02-17 Hsio Technologies, Llc High performance surface mount electrical interconnect
US9276336B2 (en) 2009-05-28 2016-03-01 Hsio Technologies, Llc Metalized pad to electrical contact interface
WO2014011232A1 (en) 2012-07-12 2014-01-16 Hsio Technologies, Llc Semiconductor socket with direct selective metalization
WO2012078493A1 (en) 2010-12-06 2012-06-14 Hsio Technologies, Llc Electrical interconnect ic device socket
WO2014011226A1 (en) 2012-07-10 2014-01-16 Hsio Technologies, Llc Hybrid printed circuit assembly with low density main core and embedded high density circuit regions
US9232654B2 (en) 2009-06-02 2016-01-05 Hsio Technologies, Llc High performance electrical circuit structure
US9930775B2 (en) 2009-06-02 2018-03-27 Hsio Technologies, Llc Copper pillar full metal via electrical circuit structure
US9318862B2 (en) 2009-06-02 2016-04-19 Hsio Technologies, Llc Method of making an electronic interconnect
US9276339B2 (en) 2009-06-02 2016-03-01 Hsio Technologies, Llc Electrical interconnect IC device socket
WO2010141295A1 (en) 2009-06-02 2010-12-09 Hsio Technologies, Llc Compliant printed flexible circuit
US9277654B2 (en) 2009-06-02 2016-03-01 Hsio Technologies, Llc Composite polymer-metal electrical contacts
WO2010141297A1 (en) 2009-06-02 2010-12-09 Hsio Technologies, Llc Compliant printed circuit wafer level semiconductor package
WO2012074963A1 (en) 2010-12-01 2012-06-07 Hsio Technologies, Llc High performance surface mount electrical interconnect
US9603249B2 (en) 2009-06-02 2017-03-21 Hsio Technologies, Llc Direct metalization of electrical circuit structures
US9231328B2 (en) 2009-06-02 2016-01-05 Hsio Technologies, Llc Resilient conductive electrical interconnect
US8618649B2 (en) 2009-06-02 2013-12-31 Hsio Technologies, Llc Compliant printed circuit semiconductor package
US9196980B2 (en) 2009-06-02 2015-11-24 Hsio Technologies, Llc High performance surface mount electrical interconnect with external biased normal force loading
WO2010141311A1 (en) 2009-06-02 2010-12-09 Hsio Technologies, Llc Compliant printed circuit area array semiconductor device package
US9613841B2 (en) 2009-06-02 2017-04-04 Hsio Technologies, Llc Area array semiconductor device package interconnect structure with optional package-to-package or flexible circuit to package connection
US9320144B2 (en) 2009-06-17 2016-04-19 Hsio Technologies, Llc Method of forming a semiconductor socket
US8293299B2 (en) 2009-09-11 2012-10-23 Kraft Foods Global Brands Llc Containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable Concentrated liquids
US9689897B2 (en) 2010-06-03 2017-06-27 Hsio Technologies, Llc Performance enhanced semiconductor socket
US10159154B2 (en) 2010-06-03 2018-12-18 Hsio Technologies, Llc Fusion bonded liquid crystal polymer circuit structure
US9350093B2 (en) 2010-06-03 2016-05-24 Hsio Technologies, Llc Selective metalization of electrical connector or socket housing
CN101904880B (en) * 2010-07-20 2013-03-13 暨南大学 Mangosteen total xanthone extract and application thereof in preparation of TR3 receptor inducer
US11013248B2 (en) 2012-05-25 2021-05-25 Kraft Foods Group Brands Llc Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings
US9761520B2 (en) 2012-07-10 2017-09-12 Hsio Technologies, Llc Method of making an electrical connector having electrodeposited terminals
KR101407146B1 (en) * 2013-03-04 2014-06-13 임지환 Aging method for natural grass tea
US10667410B2 (en) 2013-07-11 2020-05-26 Hsio Technologies, Llc Method of making a fusion bonded circuit structure
US10506722B2 (en) 2013-07-11 2019-12-10 Hsio Technologies, Llc Fusion bonded liquid crystal polymer electrical circuit structure
CN103859093B (en) * 2014-03-31 2015-05-20 湖北昊韵农业科技有限公司 Wheat bran oolong tea and preparation method thereof
CN103859094B (en) * 2014-03-31 2015-06-24 青岛大学 Green tea capable of tonifying qi and dispersing blood stasis and preparation method of green tea
CN103988940A (en) * 2014-05-08 2014-08-20 李虎 Tea with anti-tumor effect and preparation method thereof
CN104543122A (en) * 2014-12-16 2015-04-29 新昌县小将镇乌牛岗家庭农场 Tea with effects of maintaining beauty and keeping young
US9559447B2 (en) 2015-03-18 2017-01-31 Hsio Technologies, Llc Mechanical contact retention within an electrical connector
US20170333509A1 (en) * 2016-05-23 2017-11-23 Arkray, Inc. Maillard reaction product-decomposing agent
CN106035847A (en) * 2016-07-13 2016-10-26 广西南宁途御科技有限公司 Beverage containing mangosteen, grapes and green tea and production method of beverage
CN105942076A (en) * 2016-07-13 2016-09-21 广西南宁途御科技有限公司 Beverage containing mangosteen, durian and chrysanthemum flower and preparation method thereof
CN106173668A (en) * 2016-07-13 2016-12-07 广西南宁途御科技有限公司 A kind of containing Garcinia mangostana green tea beverage and preparation method thereof
CN106173667A (en) * 2016-07-13 2016-12-07 广西南宁途御科技有限公司 A kind of containing Garcinia mangostana Fructus Vitis viniferae rose flower beverage and production method thereof
CN106173665A (en) * 2016-07-13 2016-12-07 广西南宁途御科技有限公司 A kind of Garcinia mangostana durian drink and preparation method thereof
CN106070898A (en) * 2016-07-13 2016-11-09 广西南宁途御科技有限公司 A kind of containing Garcinia mangostana rose tea drink and preparation method thereof
CN107372951B (en) * 2017-07-18 2021-01-01 刘元友 Matcha powder containing herba Urticae Cannabinae and its preparation method
CN107348068A (en) * 2017-08-07 2017-11-17 三江县连兴蛇业有限公司 Yncaria stem with hooks leaf tea and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120958A (en) * 1983-12-01 1985-06-28 San Food Kk Preparation of artificial truffle
RU2007178C1 (en) * 1987-08-20 1994-02-15 Нешта Нина Михайловна Immunomodulating agent
JPH07250658A (en) * 1994-03-11 1995-10-03 Dainippon Ink & Chem Inc Antimicrobial agent
CN1144046A (en) * 1995-08-31 1997-03-05 张福星 Anticancer health-care tea and preparation method thereof
AUPN725895A0 (en) * 1995-12-21 1996-01-18 Australian Food Industry Science Centre Preservation of exposed fresh fruit
US6231866B1 (en) * 1998-04-30 2001-05-15 Douglas G. Mann Infused vegetable, fruit, herb, and/or seed fiber product and dietary supplements containing same
GB9918030D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
JP4630416B2 (en) * 2000-03-02 2011-02-09 株式会社ロッテ Anti-caries, periodontal disease agent
CN1448063A (en) * 2002-04-04 2003-10-15 深圳市润邦实业发展有限公司 Aloe health tea and production method thereof
CN1425314A (en) * 2003-01-08 2003-06-25 韩星智 Sobering up tea and its preparing method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1691758A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235533B1 (en) 1998-03-18 2001-05-22 Amcol International Corporation Method of determining the composition of clay deposit
WO2011106417A2 (en) * 2010-02-23 2011-09-01 Tahitian Noni International, Inc. Garcinia mangostana l. and iridoid based formulations
WO2011106417A3 (en) * 2010-02-23 2012-01-05 Tahitian Noni International, Inc. Garcinia mangostana l. and iridoid based formulations
EP3354254A4 (en) * 2015-09-21 2019-03-27 Industry-Academic Cooperation Foundation Gyeongsang National University Skin whitening composition containing beta-mangostin as active ingredient
US11882858B2 (en) 2015-09-21 2024-01-30 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for skin whitening comprising β-mangostin as effective ingredient
RU2737701C1 (en) * 2020-06-17 2020-12-02 Андрей Михайлович Гомжин Pharmaceutical composition of sedative and anxiolytic action

Also Published As

Publication number Publication date
US20050196511A1 (en) 2005-09-08
CN1889967A (en) 2007-01-03
EP1691758A2 (en) 2006-08-23
AU2004291117A1 (en) 2005-06-02
CA2545819A1 (en) 2005-06-02
EP1691758A4 (en) 2009-07-08
KR20060128887A (en) 2006-12-14
BRPI0416594A (en) 2007-03-06
JP2007511224A (en) 2007-05-10
WO2005048940A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
US20050196511A1 (en) Nutraceutical mangosteen tea
EP0762836B1 (en) Beverage compositions containing green tea solids, electrolytes and carbohydrates to provide improved cellular hydration and drinkability
EP2787839B1 (en) Fatigue-relieving herbal extracts and beverages comprising the same
JP6029546B2 (en) Beverage
KR101778101B1 (en) Method for producing red ginseng dutch coffee for fatigue recovery
KR20100026487A (en) Drink for mitigating hangover using jujube and manufacturing method thereof
RU2612779C2 (en) Beverage concentrate (versions)
KR101857168B1 (en) Method for producing beverage using steamed Cornus officianalis with increased antioxidant activity
KR102104175B1 (en) Method for producing functional fermented dutch coffee
KR102346505B1 (en) Raw jujube mixed drink with antioxidant function and its manufacturing method
CN1341370A (en) Lycium leaf tea
KR101025766B1 (en) The manufacturing method and the korean traditional herb tea composition for inhibiting obesity
KR20190006702A (en) Method for manufacturing the functional beverage containing Chaenomeles sinensis Koehne, Mentha arvensis var and Cornus officinalis sieb and the functional beverage prepared therefrom
CN106689535A (en) Three-root lung-heat clearing tea beverage and preparation method thereof
MXPA06005419A (en) Nutraceutical mangosteen tea
CN101744069A (en) Compound wild jujube tea
JP3467576B2 (en) SOD-like action antioxidant beverage
KR20100055026A (en) Manufacturing method of foods using chinese medicine and red ginseng and product thereof
Anilakumar et al. Non-alcoholic beverages-market potential and opportunities
CN111328899A (en) Orange, cattail and perilla herb substituted tea and preparation method thereof
KR102256014B1 (en) Functional health drink for preventing female diseases and process for preparing the same
KR102476793B1 (en) Method for manufacturing a hangover cures drink, and the hangover cures drink manufactured by the method
KR102468019B1 (en) Plant mixed concentrate mainly containing Korean Dendropanax and foods using the concentrate
CN105265686A (en) Osmanthus tea and preparation method of osmanthus tea
US20240123018A1 (en) A herbal bamboo tea composition and a method of preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480035899.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006539951

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2545819

Country of ref document: CA

Ref document number: PA/a/2006/005419

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12006500958

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004291117

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067011394

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004810952

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004291117

Country of ref document: AU

Date of ref document: 20041112

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004291117

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004810952

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067011394

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0416594

Country of ref document: BR